Clinical trials: Disease, Acute
Stroke
Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II study to evaluate the safety and efficacy of five dose levels of study drug in acute ischaemic stroke
- Trial name
- VASST (NCT00144014)
- Testing
- V10153
- Where
- 28 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Vernalis (R&D) Ltd
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Atherosclerosis, Percutaneous Coronary Intervention
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
- Conditions
- Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- CHAMPION (NCT01156571)
- Testing
- cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
- Where
- United States
- Volunteers
- 11,145 people
- Sponsor
- The Medicines Company
Coronary Stenosis, Acute Coronary Syndrome
Coronary Plaque Geometry and Acute Coronary Syndromes
The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography…
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atherosclerosis
- Trial name
- NCT03702764
- Testing
- CCTA
- Where
- Romania
- Volunteers
- 1,000 people
- Sponsor
- Cardio Med Medical Center
Plasmodium Falciparum Malaria
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study was to evaluate PK, safety, tolerability and efficacy of a new formulation of artemether-lumefantrine dispersible tablet in neonates and infants <5 kg body weight with acute uncomplicated Plasmodium…
- Trial name
- CALINA (NCT04300309)
- Testing
- artemether:lumefantrine (2.5 mg:30 mg)
- Where
- 3 sites in Burkina Faso, Democratic Republic of the Congo
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Pneumonia, Bacterial
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
- Trial name
- NCT00538694
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
- Trial name
- ARTEMIS1 (NCT01390220)
- Testing
- USL261
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 292 people
- Sponsor
- UCB Biopharma S.P.R.L.
Acute Myeloid Leukemia
Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)
This Phase I study is designed to assess the safety, tolerability, pharmacokinetics and anti-tumor effect of increasing doses of study drug SKI-G-801 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are…
- Trial name
- NCT03564288
- Testing
- SKI-G-801
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Oscotec Inc.
Acute Ischemic Stroke
REVascularization In Large VEssel Occlusion for Acute Ischemic Stroke
The objective of this study is to evaluate the safety and effectiveness of the SOFIA Flow 88 Aspiration Catheter for treatment of acute ischemic stroke.
- Trial name
- REVIVE (NCT07216170)
- Testing
- SOFIA Flow 88 Aspiration Catheter
- Volunteers
- 200 people
- Sponsor
- Microvention-Terumo, Inc.
Overactive Bladder
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence
A pre-market, prospective, non-randomized acute feasibility study for the treatment of patients with urinary incontinence (UI) as a consequence of urinary incontinence.
- Trial name
- NCT03643380
- Testing
- AHLeveeS System
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Neuspera Medical, Inc.
Acute Coronary Syndromes
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart…
- Trial name
- CLARITY-TIMI28 (NCT00714961)
- Testing
- Clopidogrel (SR25990)
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 3,491 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in newly…
- Trial name
- VERO (NCT06058741)
- Where
- 28 sites in Italy
- Volunteers
- 151 people
- Sponsor
- AbbVie
Skin Infection
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Primary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA.
- Trial name
- CG400549 (NCT01593761)
- Testing
- CG400549
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CrystalGenomics, Inc.
COVID-19
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection.
- Trial name
- NCT05007496
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Acute Myeloid Leukemia
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.
- Trial name
- SPARK-AML1 (NCT00952588)
- Testing
- AZD1152, LDAC
- Where
- 45 sites in United States, Australia and 7 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
NHL, Adult, AML, Adult Recurrent
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are…
- Trial name
- NCT05758610
- Testing
- ETH-155008
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shengke Pharmaceuticals (Jiangsu) Limited, China
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy.
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
- Trial name
- NCT05123755
- Testing
- AV-001 Injection
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vasomune Therapeutics, Inc.
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.
- Trial name
- NCT00324220
- Testing
- MGCD0103
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.